Impact of CD34+ pre-counting and plerixafor on autologous peripheral blood stem cell collection in Japanese university hospitals in eight years

Nakamura, Yuki; Okubo, Mitsuo; Furuta, Yoshiaki; Tokida, Miho; Ichikawa, Kayoko; Ohsaka, Akimichi

doi:10.1016/j.transci.2019.10.006

Cited by 8 publications

(14 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CD34+ cells were counted on the day before leukapheresis, designated as CD34+ cell pre-count, as described previously. 8 In brief, G-CSF was administrated for at least 4 days and when the WBC count exceeded 5 000/μL, approximately, the peripheral blood CD34+ cell monitoring, using flow cytometry, was initiated. 16 Clinical cell therapy specialists, who were certified by the Japanese Society of Transfusion Medicine and Cell Therapy (JSTMCT) and by the Japan Society for Hematopoietic Stem Cell Transplantation, enumerated the CD34+ cells.…”

Section: Cd34+ Cell Countmentioning

confidence: 99%

“…The patients with MM are divided into three groups as follows: CD34+ cell pre-count less than 5.5 cells/μL (<5.5), 5.5 to 20 cells/μL (5.5-20), and greater than 20 cells/μL (>20). Similarly, the patients with ML are divided into (<6), (6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20), and (>21). Each group was further divided into PLX (+) or nonuse (−).…”

Section: Confirmation Of the Effect Of Plxmentioning

confidence: 99%

“…We previously reported the use of CD34+ cell pre-counting as a strategy for improving ASC, through the prediction of leukapheresis initiation. 8 Several researchers including our group became aware that CD34+ cell pre-count could also be used for determining the efficiency of PLX administration. 9,10 To verify the suitability of CD34+ cell monitoring for optimal PLX administration, we retrospectively analyzed our ASC data, with or without PLX treatment, from two university hospitals in Japan.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Threshold for optimal administration of plerixafor in autologous peripheral blood stem cell collections through CD34+ cell monitoring based on the experience from two Japanese university hospitals

et al. 2021

Self Cite

View full text Add to dashboard Cite

Plerixafor was introduced to Japan in 2017 as a stem cell mobilization enhancement reagent, but the threshold for its use remains unclear. In this study, we assessed 57 patients treated with plerixafor (33 patients with multiple myeloma (MM) and 24 with malignant lymphoma (ML) and 152 patients without plerixafor administration. When CD34+ cell pre-counts were between 5.5 and 20 cells/μL in MM or 6 and 21 cells/μL in ML, the CD34+ cell count increased significantly, attaining the highest yield in response to plerixafor (achievement rate by one leukapheresis is 93.3% and 91.7% in MM and ML, at P < .001 and P = .012, respectively). In case the CD34+ cell pre-count was less than 5.5 cells/μL, an increase of at least 7 cells/μL from baseline by plerixafor was the necessary condition to achieve successful collection through a twotime leukapheresis. Monitoring CD34+ cell numbers might improve the collection efficiency and reduce the cost.

show abstract

Section: Cd34+ Cell Countmentioning

confidence: 99%

Section: Confirmation Of the Effect Of Plxmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Threshold for optimal administration of plerixafor in autologous peripheral blood stem cell collections through CD34+ cell monitoring based on the experience from two Japanese university hospitals

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Bone marrow derived CD 34+ cells and leukocytes in 729 children and adults with non-malignant diseases

Pabinger

Laky²,

Heuberer³

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: To our knowledge, no large studies reporting bone marrow (BM) derived cell counts of children and adults with non-malignant diseases have been published so far. Thus, the primary objective was to evaluate BM-derived CD34+ and leukocyte cell counts in 729 female and male patients of different age groups who underwent autologous cell-based therapy for non-malignant diseases. Methods: For this study, a retrospective data analysis of laboratory parameters including BM-aspirated and post-centrifuge concentrated CD34+ cells and leukocytes was performed. Associations and differences of cell counts between age groups, gender, and diagnose related group were evaluated.Results: Included were data of 187 female and 542 male patients aged between 2 and 75 years, who underwent autologous cell-based therapy for various non-malignant diseases. The median percentage of CD34+ cells of leukocytes was 1.10% in BM-aspirate (BMA) and 0.96% in post-centrifuge BMA concentrate (BMAC). Significant moderate positive correlations were observed between CD34+ cells (count/µl) and leukocytes (count/µl) in BMA and in BMAC. Significant strong negative correlations were detected between age (years) and CD34+ cells (count/µl/kg) in BMA and in BMAC. No significant differences regarding CD34+ cells (count/µl) in BMA were detected between adults, while significant differences regarding cell counts were detected between diagnose related groups, but not between females and males.Conclusions: This study demonstrated BM-derived CD34+ and leukocyte cell counts in BMA and BMAC of 729 patients with various non-malignant diseases. While BM-derived CD34+ cells were significantly higher in younger patients, similar cell counts were detected within adults.

show abstract

“…Flow cytometry analysis for quantifying single-cells such as the hematopoietic surface marker CD34 has been widely used in clinical practice, especially in peripheral blood of patients with malignant diseases. 2 To our knowledge, comprehensive studies reporting on typical amounts of CD34+ cells in BM are sparse. Sutherland et al 3 stated that approximately a range of 1 to 3% of BM cells express CD34+ antigen (without reporting a sample size) and Brooimans et al 4 detected 1.4% of CD34+ in BM-aspirate (BMA) in a small series of patients.…”

Section: Introductionmentioning

confidence: 99%

Bone marrow derived CD 34+ cells and leukocytes in 729 children and adults with non-malignant diseases 

Pabinger

Laky²,

Heuberer³

et al. 2021

Preprint

View full text Add to dashboard Cite

To our knowledge, no large studies reporting bone marrow (BM) derived cell counts of children and adults with non-malignant diseases have been published so far. Thus, the primary objective was to evaluate BM-derived CD34+ and leukocyte cell counts in 729 female and male patients of different age groups who underwent autologous cell-based therapy for non-malignant diseases.For this study, a retrospective data analysis of laboratory parameters including BM-aspirated and post-centrifuge concentrated CD34+ cells and leukocytes was performed. Associations and differences of cell counts between age groups, gender, and diagnose related group were evaluated.Included were data of 187 female and 542 male patients aged between 2 and 75 years, who underwent autologous cell-based therapy for various non-malignant diseases. The median percentage of CD34+ cells of leukocytes was 1.10% in BM-aspirate (BMA) and 0.96% in post-centrifuge BMA concentrate (BMAC). Significant moderate positive correlations were observed between CD34+ cells (count/μl) and leukocytes (count/μl) in BMA and in BMAC. Significant strong negative correlations were detected between age (years) and CD34+ cells (count/μl/kg) in BMA and in BMAC. No significant differences regarding CD34+ cells (count/μl) in BMA were detected between adults, while significant differences regarding cell counts were detected between diagnose related groups, but not between females and males.This study including 729 patients with various non-malignant diseases showed that approximately 1% of leukocytes were CD34+ cells in BMA and in BMAC. While BM-derived CD34+ cells were significantly higher in younger patients, similar cell counts were detected within adults.

show abstract

Impact of CD34+ pre-counting and plerixafor on autologous peripheral blood stem cell collection in Japanese university hospitals in eight years

Cited by 8 publications

References 22 publications

Threshold for optimal administration of plerixafor in autologous peripheral blood stem cell collections through CD34+ cell monitoring based on the experience from two Japanese university hospitals

Threshold for optimal administration of plerixafor in autologous peripheral blood stem cell collections through CD34+ cell monitoring based on the experience from two Japanese university hospitals

Bone marrow derived CD 34+ cells and leukocytes in 729 children and adults with non-malignant diseases

Bone marrow derived CD 34+ cells and leukocytes in 729 children and adults with non-malignant diseases

Contact Info

Product

Resources

About

Impact of CD34+ pre-counting and plerixafor on autologous peripheral blood stem cell collection in Japanese university hospitals in eight years

Cited by 8 publications

References 22 publications

Threshold for optimal administration of plerixafor in autologous peripheral blood stem cell collections through CD34+ cell monitoring based on the experience from two Japanese university hospitals

Threshold for optimal administration of plerixafor in autologous peripheral blood stem cell collections through CD34+ cell monitoring based on the experience from two Japanese university hospitals

Bone marrow derived CD 34+ cells and leukocytes in 729 children and adults with non-malignant diseases

Bone marrow derived CD 34+ cells and leukocytes in 729 children and adults with non-malignant diseases&nbsp;

Contact Info

Product

Resources

About

Bone marrow derived CD 34+ cells and leukocytes in 729 children and adults with non-malignant diseases